Advancing Cancer Treatment
Next-Generation Sequencing (NGS) for advanced cancer care in 2024
- By: Admin
We're thrilled to share the latest recommendations from the European Society for Medical Oncology (ESMO) on the use of Next-Generation Sequencing (NGS) for advanced cancer care in 2024! These updates are set to revolutionize how we approach cancer treatment, making it more personalized and effective than ever before.
Key Highlights:
ESMO expands its recommendations to include multiple NGS (CGP) approaches and the use of tumor NGS, offering comprehensive genetic analysis to guide targeted therapies for patients with advanced cancers such as :
Advanced breast cancer
Prostate cancer
Ovarian cancer
Cholangiocarcinoma
Thyroid cancer
Cancer of Unknown primary (CUP)
Gastrointestinal Stromal Tumor (GIST)
Soft tissue sarcoma
Colorectal cancer
ESMO also recommends NGS in patients with advanced cancer for tumor-agnostic targeted therapies.
Why NGS Matters:
Precision Medicine: Tailoring treatments to patients' unique genetic profiles, accelerating discoveries, and enhancing treatment protocols.
NGS panels detect HRD, fusion genes, and provide insights into germline variants and clonal hematopoiesis.
Cost-Effectiveness: Implementing NGS with a focus on accessibility and local cost-effectiveness.
At Kyvor Genomics, we're dedicated to leveraging the latest advancements in NGS to improve patient outcomes and bring hope to those fighting cancer. Together, let's embrace the future of precision oncology.
The War against Cancer can be Won